Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A manufacturer-sponsored 28-week RCT used mixed-meal testing to compare how tirzepatide and semaglutide improve glucose control in type 2 diabetes. PICO summary and expert commentary.
A pre-specified FLOW subgroup analysis tests whether baseline SGLT2 inhibitor use modifies semaglutide's kidney and cardiovascular benefit in type 2 diabetes with CKD. PICO summary and expert commentary.
A post hoc analysis of a 32-week randomised trial examined how semaglutide, empagliflozin and their combination altered renal diffusion-weighted MRI and total kidney volume in type 2 diabetes. PICO summary and expert commentary.
PIONEER 12 was a 26-week double-blind Phase IIIa trial showing all three doses of once-daily oral semaglutide lowered HbA1c and body weight more than sitagliptin 100 mg in a predominantly Chinese type 2 diabetes population. PICO summary and expert commentary.
Phase IIIa double-blind trial of oral semaglutide monotherapy vs placebo in a predominantly Chinese type 2 diabetes population, with HbA1c and body-weight findings. PICO summary and expert commentary.
STEP 10 phase 3 RCT: once-weekly semaglutide 2.4 mg cut bodyweight by 13.9% and drove reversion to normoglycaemia in adults with obesity and prediabetes. PICO summary and expert commentary.
A phase 2b randomized trial of the GLP-1/glucagon dual agonist cotadutide in type 2 diabetes and CKD, with dose-dependent reductions in albuminuria at week 14. PICO summary and expert commentary.
A single-centre RCT (n=180) testing an integrated cloud data platform with dietary management and education videos against routine care in type 2 diabetes, with HbA1c lower at 12 weeks. PICO summary and expert commentary.
A post hoc analysis of the SUSTAIN 6 trial reports that once-weekly semaglutide was associated with lower odds of developing diabetic kidney disease in adults with type 2 diabetes who had no kidney disease at baseline. PICO summary and expert commentary.
A 12-week pilot RCT comparing an 800 kcal/day very-low calorie diet, semaglutide, and their combination in 30 adults with type 2 diabetes. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
